Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776115 | 0.85 | LMNA (0.56) | KMT2ASMN1; SMN2RAB9APOLBHTT | |
| SCHEMBL5777123 | 0.85 | HPGD (0.50) | KMT2AMEN1SMN1; SMN2RAB9APOLB | |
| SCHEMBL5774126 | 0.81 | MEN1 (0.43) | KMT2AMEN1SMN1; SMN2RAB9APOLB | |
| SCHEMBL5772900 | 0.79 | BACE1 (0.46) | BACE1KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL5773415 | 0.78 | MTNR1A (0.38) | SMN1; SMN2POLBTSHRKDM4ELMNA | |
| SCHEMBL5773408 | 0.77 | LMNA (0.48) | SMN1; SMN2RAB9APOLBNPC1MAPK1 | |
| SCHEMBL5774072 | 0.77 | LMNA (0.54) | KMT2AMEN1SMN1; SMN2RAB9APOLB | |
| SCHEMBL5771304 | 0.76 | APOL1 (0.48) | RAB9A | |
| SCHEMBL5769962 | 0.76 | SMN1; SMN2 (0.41) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5773900 | 0.76 | CYP1A2 (0.52) | KMT2AMEN1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | BACE1 1040/4885KMT2A 3907/4885MEN1 2811/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | BACE1 619/4885KMT2A 2906/4885MEN1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.